No Data
Sunflower Health Plan and Centene Foundation Announce $200,000 Grant to GoodLife Innovations
Centene (NYSE:CNC) Hasn't Managed To Accelerate Its Returns
Barclays Maintains Centene(CNC.US) With Buy Rating, Cuts Target Price to $90
Barclays analyst Andrew Mok CFA maintains $Centene(CNC.US)$ with a buy rating, and adjusts the target price from $104 to $90.According to TipRanks data, the analyst has a success rate of 46.1% and a t
How Is Centene's Stock Performance Compared to Other Healthcare Stocks?
Barclays Adjusts Price Target on Centene to $90 From $104, Maintains Overweight Rating
Why Investors Need to Take Advantage of These 2 Medical Stocks Now